Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Munster study group.

ABSTRACT: Despite intensified salvage treatments, children with relapsed/refractory acute myeloid leukemia (AML) have poor survival. We evaluated gemtuzumab ozogamicin (CD33-targeted drug) used on a compassionate basis in patients diagnosed from 1995 until 2014 within Acute Myeloid Leukemia Berlin-Frankfurt-Münster studies, and identified 76 patients (<18 years) with highly-advanced and pre-treated AML [refractory de novo acute myeloid leukemia (n=10), de novo AML refractory to relapse (1^st early: n=41; 1^st late: n=10; 2^nd or more: n=10), and secondary AML (n=5)]. At doses of 2.5-10 mg/m², gemtuzumab ozogamicin was administered in 1-4 cycles as single agent (47%), combined with cytarabine (47%), or others (6%). Most common grade 3/4 adverse e

SUBMITTER: Niktoreh N 

PROVIDER: S-EPMC6312035 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature